n-methyl-3,4-methylenedioxyamphetamine has been researched along with levodopa in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, HS; Wang, RY | 1 |
| Black, CK; Schmidt, CJ; Taylor, VL | 1 |
| Aguirre, N; Barrionuevo, M; Del Río, J; Lasheras, B | 1 |
| Colado, MI; Esteban, B; Granados, R; Green, AR; Martín, AB; O'Shea, E | 1 |
| Iravani, MM; Jackson, MJ; Jenner, P; Kuoppamäki, M; Smith, LA | 1 |
| Bishop, C; Eskow, KL; Kuhn, DM; Park, JY; Taylor, JL; Walker, PD | 1 |
| Blanco, M; Felim, A; Herrera, G; Largeron, M; Neudörffer, A; O'Connor, JE | 1 |
| Brotchie, JM; Fox, SH; Huot, P; Johnston, TH; Koprich, JB; Lewis, KD; Piggott, MJ; Reyes, MG | 1 |
| Brotchie, JM; Fox, SH; Gandy, MN; Gomez-Ramirez, J; Huot, P; Johnston, TH; Lee, J; Lewis, KD; Martin-Iverson, M; McIldowie, M; Millar, Z; Nash, JE; Piggott, MJ; Salomonczyk, D; Thiele, S; Wagg, K; Yong-Kee, CJ | 1 |
| Fischer, K; Lettfuss, NY; Pichler, BJ; Sossi, V; von Ameln-Mayerhofer, A | 1 |
| Aguirre, N; Barros-Miñones, L; Beitia, G; Goñi-Allo, B; Puerta, E; Suquia, V | 1 |
| Ballanger, B; Bars, DL; Beaudoin-Gobert, M; Bonnefoi, F; Broussolle, E; Costes, N; Duperrier, S; Epinat, J; Lavenne, F; Liger, F; Météreau, E; Neumane, S; Sgambato-Faure, V; Thobois, S; Tourvielle, C; Tremblay, L | 1 |
| Beaudoin-Gobert, M; Duperrier, S; Météreau, E; Sgambato, V; Thobois, S; Tremblay, L | 1 |
| Sgambato, V | 1 |
14 other study(ies) available for n-methyl-3,4-methylenedioxyamphetamine and levodopa
| Article | Year |
|---|---|
The action of (+/-)-MDMA on medial prefrontal cortical neurons is mediated through the serotonergic system.
Topics: 3,4-Methylenedioxyamphetamine; 5-Hydroxytryptophan; alpha-Methyltyrosine; Analysis of Variance; Animals; Cerebral Cortex; Designer Drugs; Dopamine; Electrophysiology; Fenclonine; Levodopa; Male; Methyltyrosines; N-Methyl-3,4-methylenedioxyamphetamine; Neurons; Rats; Rats, Inbred Strains; Reference Values; Serotonin | 1991 |
L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain Chemistry; Cerebral Cortex; Corpus Striatum; Dopamine; Drug Synergism; Fenfluramine; Hippocampus; Levodopa; Male; Methamphetamine; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Degeneration; Nerve Endings; Nervous System Diseases; p-Chloroamphetamine; Rats; Rats, Inbred Strains; Serotonin | 1991 |
The role of dopaminergic systems in the perinatal sensitivity to 3, 4-methylenedioxymethamphetamine-induced neurotoxicity in rats.
Topics: Age Factors; Amphetamines; Animals; Body Temperature; Brain; Carrier Proteins; Dopamine; Female; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Rats; Rats, Wistar; Receptors, Serotonin; Serotonin; Serotonin Plasma Membrane Transport Proteins | 1998 |
Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration.
Topics: Animals; Body Temperature; Brain; Dopamine; Free Radicals; Haloperidol; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Neurodegenerative Diseases; Paroxetine; Rats; Serotonin | 1999 |
3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Callithrix; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Levodopa; Male; Motor Activity; N-Methyl-3,4-methylenedioxyamphetamine; Parkinsonian Disorders; Receptor, Serotonin, 5-HT1B; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Serotonin Receptor Agonists | 2003 |
MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Fenfluramine; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Serotonin, 5-HT1A; Serotonin 5-HT1 Receptor Antagonists; Serotonin Agents | 2006 |
Synthesis and in vitro cytotoxicity profile of the R-enantiomer of 3,4-dihydroxymethamphetamine (R-(-)-HHMA): comparison with related catecholamines.
Topics: Catecholamines; Cell Line, Tumor; Deoxyepinephrine; Flow Cytometry; Humans; Levodopa; N-Methyl-3,4-methylenedioxyamphetamine; Stereoisomerism; Toxicity Tests | 2010 |
Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
Topics: Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Brain; Callithrix; Dyskinesia, Drug-Induced; Female; Levodopa; Motor Activity; MPTP Poisoning; N-Methyl-3,4-methylenedioxyamphetamine; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Stereoisomerism | 2011 |
A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates.
Topics: Animals; Antiparkinson Agents; Benzodioxoles; Cell Line, Tumor; Drug Synergism; Levodopa; Male; Methylamines; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2012 |
Imaging DA release in a rat model of L-DOPA-induced dyskinesias: a longitudinal in vivo PET investigation of the antidyskinetic effect of MDMA.
Topics: Adrenergic Uptake Inhibitors; Animals; Brain; Dopamine; Dyskinesia, Drug-Induced; Levodopa; Male; N-Methyl-3,4-methylenedioxyamphetamine; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley | 2012 |
Contribution of dopamine to mitochondrial complex I inhibition and dopaminergic deficits caused by methylenedioxymethamphetamine in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aconitate Hydratase; alpha-Methyltyrosine; Animals; Body Temperature; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Electron Transport Complex I; Gene Expression Regulation; Hallucinogens; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; N-Methyl-3,4-methylenedioxyamphetamine; Piperazines; Tyrosine 3-Monooxygenase | 2015 |
Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.
Topics: Aniline Compounds; Animals; Antiparkinson Agents; Brain; Brain Mapping; Chlorocebus aethiops; Disease Models, Animal; Dopamine; Dopamine Agents; Female; Levodopa; Macaca fascicularis; Male; Mental Disorders; MPTP Poisoning; N-Methyl-3,4-methylenedioxyamphetamine; Nortropanes; Radionuclide Imaging; Serotonin; Serotonin Agents; Sulfides | 2015 |
Pathophysiology of levodopa-induced dyskinesia: Insights from multimodal imaging and immunohistochemistry in non-human primates.
Topics: Animals; Brain; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Macaca fascicularis; MPTP Poisoning; Multimodal Imaging; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Fibers; Parkinson Disease, Secondary; Positron-Emission Tomography; Serotonin Agents; Serotonin Plasma Membrane Transport Proteins | 2018 |
Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine.
Topics: Animals; Diffusion Tensor Imaging; Disease Models, Animal; Dopamine; Haplorhini; Humans; Levodopa; N-Methyl-3,4-methylenedioxyamphetamine; Parkinson Disease; Serotonin | 2021 |